Development and deployment of COVID-19 vaccines for those most vulnerable

Wayne C Koff^{1

2}, Theodore Schenkelberg^{3

2}, Tere Williams⁴, Ralph S Baric⁵, Adrian McDermott⁶, Cheryl M Cameron⁷, Mark J Cameron⁷, Matthew B Friemann⁸, Gabriele Neumann⁹, Yoshihiro Kawaoka^{9

10}, Alyson A Kelvin¹¹, Ted M Ross¹², Stacey Schultz-Cherry¹³, Timothy D Mastro¹⁴, Frances H Priddy¹⁵, Kristine A Moore¹⁶, Julia T Ostrowsky¹⁶, Michael T Osterholm¹⁶, Jaap Goudsmit^{3

17}

Affiliations

¹ Human Vaccines Project, New York, NY 10119, USA. wkoff@humanvaccinesproject.org.
² Human Immunomics Initiative, Department of Epidemiology, Harvard TH Chan School of Public Health, Boston, MA 02115, USA.
³ Human Vaccines Project, New York, NY 10119, USA.
⁴ Department of Pathology, Albert Einstein College of Medicine Bronx, NY 10461, USA.
⁵ Department of Epidemiology, University of North Carolina, Chapel Hill, NC 27599, USA.
⁶ Vaccine Immunology Program, Vaccine Research Center, National Institutes of Health, Bethesda, MD 20814, USA.
⁷ School of Medicine, Case Western Reserve University, Cleveland, OH 44106, USA.
⁸ Department of Microbiology and Immunology, University of Maryland at Baltimore, Baltimore, MD School of Medicine, Baltimore, MD 21201, USA.
⁹ Influenza Research Institute, Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin, Madison, WI 53706, USA.
¹⁰ Institute of Medical Science, University of Tokyo, Bunkyo City, Tokyo 113-8654, Japan.
¹¹ Departments of Pediatrics, Microbiology and Immunology, Dalhousie University, Halifax, NS B3H 4R2, Canada.
¹² Animal Health Research Center, Center for Vaccines, Immunology and Infectious Disease, College of Veterinary Medicine, University of Georgia, Athens, GA 30602, USA.
¹³ Infectious Diseases Research, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
¹⁴ FHI 360, Durham, NC 27701, USA.
¹⁵ Vaccine Alliance Aotearoa New Zealand, Malaghan Institute of Medical Research, Wellington 6242, New Zealand.
¹⁶ Center for Infectious Disease Research and Policy (CIDRAP), University of Minnesota, Minneapolis MN 55455, USA.
¹⁷ Human Immunomics Initiative, Departments of Epidemiology, Immunology and Infectious Diseases, Harvard TH Chan School of Public Health, Boston, MA 02115, USA.

PMID: 33536277
DOI: 10.1126/scitranslmed.abd1525

Review

Development and deployment of COVID-19 vaccines for those most vulnerable

Wayne C Koff et al. Sci Transl Med. 2021.

. 2021 Feb 3;13(579):eabd1525.

doi: 10.1126/scitranslmed.abd1525.

Authors

Affiliations

¹ Human Vaccines Project, New York, NY 10119, USA. wkoff@humanvaccinesproject.org.
² Human Immunomics Initiative, Department of Epidemiology, Harvard TH Chan School of Public Health, Boston, MA 02115, USA.
³ Human Vaccines Project, New York, NY 10119, USA.
⁴ Department of Pathology, Albert Einstein College of Medicine Bronx, NY 10461, USA.
⁵ Department of Epidemiology, University of North Carolina, Chapel Hill, NC 27599, USA.
⁶ Vaccine Immunology Program, Vaccine Research Center, National Institutes of Health, Bethesda, MD 20814, USA.
⁷ School of Medicine, Case Western Reserve University, Cleveland, OH 44106, USA.
⁸ Department of Microbiology and Immunology, University of Maryland at Baltimore, Baltimore, MD School of Medicine, Baltimore, MD 21201, USA.
⁹ Influenza Research Institute, Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin, Madison, WI 53706, USA.
¹⁰ Institute of Medical Science, University of Tokyo, Bunkyo City, Tokyo 113-8654, Japan.
¹¹ Departments of Pediatrics, Microbiology and Immunology, Dalhousie University, Halifax, NS B3H 4R2, Canada.
¹² Animal Health Research Center, Center for Vaccines, Immunology and Infectious Disease, College of Veterinary Medicine, University of Georgia, Athens, GA 30602, USA.
¹³ Infectious Diseases Research, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
¹⁴ FHI 360, Durham, NC 27701, USA.
¹⁵ Vaccine Alliance Aotearoa New Zealand, Malaghan Institute of Medical Research, Wellington 6242, New Zealand.
¹⁶ Center for Infectious Disease Research and Policy (CIDRAP), University of Minnesota, Minneapolis MN 55455, USA.
¹⁷ Human Immunomics Initiative, Departments of Epidemiology, Immunology and Infectious Diseases, Harvard TH Chan School of Public Health, Boston, MA 02115, USA.

PMID: 33536277
DOI: 10.1126/scitranslmed.abd1525

Abstract

Development of safe and effective COVID-19 vaccines is a global priority and the best hope for ending the COVID-19 pandemic. Remarkably, in less than 1 year, vaccines have been developed and shown to be efficacious and are already being deployed worldwide. Yet, many challenges remain. Immune senescence and comorbidities in aging populations and immune dysregulation in populations living in low-resource settings may impede vaccine effectiveness. Distribution of vaccines among these populations where vaccine access is historically low remains challenging. In this Review, we address these challenges and provide strategies for ensuring that vaccines are developed and deployed for those most vulnerable.

PubMed Disclaimer

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

Grants and funding

WT_/Wellcome Trust/United Kingdom

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Development and deployment of COVID-19 vaccines for those most vulnerable

Affiliations

Development and deployment of COVID-19 vaccines for those most vulnerable

Authors

Affiliations

Abstract

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical